{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:59:50Z","timestamp":1785329990662,"version":"3.55.0"},"posted":{"date-parts":[[2026,7,27]]},"group-title":"Epidemiology","reference-count":102,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["R01DA050629"],"award-info":[{"award-number":["R01DA050629"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,7,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Clinical guidelines for managing opioid use disorder (OUD) recommend incremental dose titration for methadone and buprenorphine\/naloxone to achieve a safe therapeutic maintenance dose. Dose titration recommendations are based on clinical experience, pharmacologic rationale, and expert consensus, with limited real-world evidence, especially in settings with widespread fentanyl use, where traditional titration schedules may be insufficient to address the higher opioid tolerance among people initiating treatment. This study aims to determine the comparative effectiveness of alternative titration schedules on completed induction and time to all-cause mortality.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>We will conduct a population-based retrospective cohort study using linked data from nine provincial health administrative databases. The study population will include adults (\u226518 years) in British Columbia, Canada, who initiated methadone or buprenorphine\/naloxone between 01\/01\/2010 and 30\/06\/2022. Primary outcomes are completed induction (defined as no dose increase for \u2265two weeks without any intervening decrease) and time to all-cause mortality, with overdose-related acute care visits or overdose-related death and treatment discontinuation as secondary outcomes. Using a target trial framework, this study will implement a \u2018clone-censor-weight\u2019 approach to estimate the per-protocol effects of sustained titration schedules capturing adherence to and deviation from clinical guidelines. Sensitivity analyses will assess the robustness of findings through cohort and timeline restrictions as well as alternative exposure and outcome definitions.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>This study will generate real-world evidence on the comparative effectiveness of alternative titration schedules of methadone and buprenorphine\/naloxone on completed induction and all-cause mortality. The findings will support evidence-informed updates to OAT guidelines and clinical decision-making in British Columbia and other jurisdictions facing escalating opioid-related harms.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.07.23.26358700","type":"posted-content","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:00:20Z","timestamp":1785168020000},"source":"Crossref","is-referenced-by-count":0,"title":["What constitutes safe and effective dose titration of methadone and buprenorphine\/naloxone? protocol for a population-based target trial emulation"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2624-2118","authenticated-orcid":false,"given":"Momenul Haque","family":"Mondol","sequence":"first","affiliation":[{"name":"School of Population and Public Health, University of British Columbia, Vancouver, Canada"},{"name":"Centre for Advancing Health Outcomes, Vancouver, British Columbia, Canada"},{"name":"Department of Statistics and Data Science, University of Barishal, Barishal, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Zanette","sequence":"additional","affiliation":[{"name":"Centre for Advancing Health Outcomes, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Eun","family":"Min","sequence":"additional","affiliation":[{"name":"Centre for Advancing Health Outcomes, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Kurz","sequence":"additional","affiliation":[{"name":"Centre for Advancing Health Outcomes, Vancouver, British Columbia, Canada"},{"name":"Faculty of Health Sciences, Simon Fraser University; Burnaby, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert William","family":"Platt","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Seaman","sequence":"additional","affiliation":[{"name":"MRC Biostatistics Unit, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paxton","family":"Bach","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ehsanul","family":"Karim","sequence":"additional","affiliation":[{"name":"School of Population and Public Health, University of British Columbia, Vancouver, Canada"},{"name":"Centre for Advancing Health Outcomes, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eugenia","family":"Soc\u00edas","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gustafson","sequence":"additional","affiliation":[{"name":"Department of Statistics, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M","family":"Sutherland","sequence":"additional","affiliation":[{"name":"Centre for Health Services and Policy Research, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2513-3718","authenticated-orcid":false,"given":"Bohdan","family":"Nosyk","sequence":"additional","affiliation":[{"name":"Centre for Advancing Health Outcomes, Vancouver, British Columbia, Canada"},{"name":"Faculty of Health Sciences, Simon Fraser University; Burnaby, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026072905050795000_2026.07.23.26358700v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32229-9"},{"key":"2026072905050795000_2026.07.23.26358700v1.2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4"},{"key":"2026072905050795000_2026.07.23.26358700v1.3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550"},{"key":"2026072905050795000_2026.07.23.26358700v1.4","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13088"},{"key":"2026072905050795000_2026.07.23.26358700v1.5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m772"},{"key":"2026072905050795000_2026.07.23.26358700v1.6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-090704"},{"key":"2026072905050795000_2026.07.23.26358700v1.7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.18389"},{"key":"2026072905050795000_2026.07.23.26358700v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108799"},{"key":"2026072905050795000_2026.07.23.26358700v1.9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c5475"},{"key":"2026072905050795000_2026.07.23.26358700v1.10","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2000.951778.x"},{"key":"2026072905050795000_2026.07.23.26358700v1.11","doi-asserted-by":"publisher","DOI":"10.1177\/08897077231185655"},{"key":"2026072905050795000_2026.07.23.26358700v1.12","unstructured":"Kumar R , Viswanath O , Saadabadi A. Buprenorphine. [Updated 2020 Oct 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459126\/"},{"key":"2026072905050795000_2026.07.23.26358700v1.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.16954"},{"key":"2026072905050795000_2026.07.23.26358700v1.14","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000952"},{"key":"2026072905050795000_2026.07.23.26358700v1.15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.6108"},{"key":"2026072905050795000_2026.07.23.26358700v1.16","doi-asserted-by":"publisher","DOI":"10.1111\/add.16491"},{"key":"2026072905050795000_2026.07.23.26358700v1.17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.26077"},{"key":"2026072905050795000_2026.07.23.26358700v1.18","unstructured":"British Columbia Centre on Substance Use (BCCSU). A guideline for the clinical management of opioid use disorder. 2023. https:\/\/www.bccsu.ca\/wp-content\/uploads\/2023\/12\/BC-OUD-Treatment-Guideline_2023-Update.pdf."},{"key":"2026072905050795000_2026.07.23.26358700v1.19","unstructured":"British Columbia Centre on Substance Use (BCCSU). A guideline for the clinical management of opioid use disorder. 2017. http:\/\/www.bccsu.ca\/wp-content\/uploads\/2017\/06\/BC-OUD-Guidelines_June2017.pdf."},{"key":"2026072905050795000_2026.07.23.26358700v1.20","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000507"},{"key":"2026072905050795000_2026.07.23.26358700v1.21","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001207"},{"key":"2026072905050795000_2026.07.23.26358700v1.22","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-021-01032-7"},{"key":"2026072905050795000_2026.07.23.26358700v1.23","unstructured":"Kahan M RLWM. , Regenstreif L , Weiss M. Recommendations for the provision of opioid agonist therapy in publicly funded residential addiction treatment centres in Ontario. Mentoring, Education, and Clinical Tools for Addiction: Partners in Health Integration (META: PHI). 2022."},{"key":"2026072905050795000_2026.07.23.26358700v1.24","unstructured":"Bromley L KMRLSAWJ. , Kahan M , Regenstreif L , Srivastava A , Wyman J. Methadone treatment for people who use fentanyl: Recommendations. Toronto, ON: META: PHI; 2021."},{"key":"2026072905050795000_2026.07.23.26358700v1.25","unstructured":"Centre for Addiction and Mental Health. Opioid Agonist Therapy: A Synthesis of Canadian Guidelines for Treating Opioid Use Disorder. [Internet]. 2021 May. www.camh.ca. Accessed 20 Dec 2023"},{"key":"2026072905050795000_2026.07.23.26358700v1.26","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000633"},{"key":"2026072905050795000_2026.07.23.26358700v1.27","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000166"},{"key":"2026072905050795000_2026.07.23.26358700v1.28","unstructured":"Queensland Opioid Dependence Treatment Guidelines 2023. Publisher: The State of Queensland (Queensland Health). Available: https:\/\/www.health.qld.gov.au\/data\/assets\/pdf_file\/0024\/1246605\/Queensland-Opioid-Dependence-Treatment-Guidelines-2023.pdf."},{"key":"2026072905050795000_2026.07.23.26358700v1.29","unstructured":"Gowing L ARDAFMLN . National Guidelines for Medication-Assisted Treatment of Opioid Dependence. Commonwealth of Australia; 2014."},{"key":"2026072905050795000_2026.07.23.26358700v1.30","unstructured":"New South Wales Ministry of H. NSW Clinical Guidelines: Treatment of Opioid Dependence - 2018. NSW Ministry of Health; 2018."},{"key":"2026072905050795000_2026.07.23.26358700v1.31","unstructured":"Clinical Guidelines on Drug Misuse and Dependence, Update 2017 Independent Expert Working Group. Drug misuse and dependence: UK guidelines on clinical management. Global and Public Health\/ Population Health\/ Healthy Behaviours, 2017."},{"key":"2026072905050795000_2026.07.23.26358700v1.32","unstructured":"Ministry of Health. New Zealand practice guidelines for opioid substitution treatment. 2014."},{"key":"2026072905050795000_2026.07.23.26358700v1.33","unstructured":"Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group (2017). Drug misuse and dependence: UK guidelines on clinical management. London: Department of Health."},{"key":"2026072905050795000_2026.07.23.26358700v1.34","unstructured":"Canadian Research Initiative in Substance Misuse. CRISM national guideline for the clinical management of opioid use disorder. Canadian Institutes on Health Research; 2018."},{"key":"2026072905050795000_2026.07.23.26358700v1.35","unstructured":"Lam V , Sankey C , Wyman J , et al. COVID-19 Opioid Agonist Treatment Guidance: META:PHI, Centre for Addiction and Mental Health and Ontario Medical Association (OMA); 2021. Available from: https:\/\/www.camh.ca\/-\/media\/health-info-files\/covid-19-2023\/covid-19-modifications-to-opioid-agonist-treatment-delivery-pdf.pdf."},{"key":"2026072905050795000_2026.07.23.26358700v1.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103573"},{"key":"2026072905050795000_2026.07.23.26358700v1.37","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(23)00023-3"},{"key":"2026072905050795000_2026.07.23.26358700v1.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104302"},{"key":"2026072905050795000_2026.07.23.26358700v1.39","doi-asserted-by":"publisher","DOI":"10.1111\/dar.13382"},{"key":"2026072905050795000_2026.07.23.26358700v1.40","unstructured":"Crawshaw J. Addendum to the New Zealand Practice Guidelines for Opioid Substitution Treatment 2014 Wellington, New Zealand: Ministry of Health; 2014. Available from: https:\/\/www.tewhatuora.govt.nz\/assets\/For-the-health-sector\/COVID-19-Information\/COVID-19-\/addendum_to_the_new_zealand_practice_guidelines_for_opioid_substitution_treatment_2014.pdf."},{"key":"2026072905050795000_2026.07.23.26358700v1.41","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2021.306654"},{"key":"2026072905050795000_2026.07.23.26358700v1.42","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12288"},{"key":"2026072905050795000_2026.07.23.26358700v1.43","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001473"},{"key":"2026072905050795000_2026.07.23.26358700v1.44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004748"},{"key":"2026072905050795000_2026.07.23.26358700v1.45","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001267"},{"key":"2026072905050795000_2026.07.23.26358700v1.46","doi-asserted-by":"publisher","DOI":"10.1186\/1940-0640-9-21"},{"key":"2026072905050795000_2026.07.23.26358700v1.47","doi-asserted-by":"publisher","DOI":"10.1177\/29767342251326339"},{"key":"2026072905050795000_2026.07.23.26358700v1.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.04.014"},{"key":"2026072905050795000_2026.07.23.26358700v1.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.209004"},{"key":"2026072905050795000_2026.07.23.26358700v1.50","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-024-09341-1"},{"key":"2026072905050795000_2026.07.23.26358700v1.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2013.01.028"},{"key":"2026072905050795000_2026.07.23.26358700v1.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2020.106740"},{"key":"2026072905050795000_2026.07.23.26358700v1.53","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-025-00548-z"},{"key":"2026072905050795000_2026.07.23.26358700v1.54","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-088617"},{"key":"2026072905050795000_2026.07.23.26358700v1.55","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-025-01386-7"},{"key":"2026072905050795000_2026.07.23.26358700v1.56","doi-asserted-by":"publisher","DOI":"10.1111\/add.13789"},{"key":"2026072905050795000_2026.07.23.26358700v1.57","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.21383"},{"key":"2026072905050795000_2026.07.23.26358700v1.58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2113319"},{"key":"2026072905050795000_2026.07.23.26358700v1.59","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254"},{"key":"2026072905050795000_2026.07.23.26358700v1.60","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3182114039"},{"key":"2026072905050795000_2026.07.23.26358700v1.61","doi-asserted-by":"publisher","DOI":"10.1177\/09622802251356594"},{"key":"2026072905050795000_2026.07.23.26358700v1.62","unstructured":"British Columbia Ministry of Health [creator] (2024). PharmaNet. British Columbia Ministry of Health [publisher]. Data Extract. MOH (2024). Available: http:\/\/www.health.gov.bc.ca\/data\/."},{"key":"2026072905050795000_2026.07.23.26358700v1.63","unstructured":"Canadian Institute of Health Information [creator] (2024). Discharge Abstract Database (Hospital Separations). British Columbia Ministry of Health [publisher]. Data Extract. MOH (2024). Available: http:\/\/www.health.gov.bc.ca\/data\/."},{"key":"2026072905050795000_2026.07.23.26358700v1.64","unstructured":"British Columbia Ministry of Health. Medical Services Plan (MSP) Payment Information File. 2024. Available: http:\/\/www.health.gov.bc.ca\/data\/."},{"key":"2026072905050795000_2026.07.23.26358700v1.65","unstructured":"British Columbia Ministry of Health [creator] (2024). Vital Statistics Deaths. British Columbia Ministry of Health [publisher]. Data Extract. MOH (2024). Available: http:\/\/www.health.gov.bc.ca\/data\/."},{"key":"2026072905050795000_2026.07.23.26358700v1.66","unstructured":"Ministry of Public Safety and Solicitor General (PSSG) [creator] (2024). BC Corrections Dataset. British Columbia Ministry of Health [publisher]. Data Extract. MOH (2024). Available: http:\/\/www.health.gov.bc.ca\/data\/."},{"key":"2026072905050795000_2026.07.23.26358700v1.67","unstructured":"Perinatal Services BC [creator] (2024). British Columbia Perinatal Data Registry. Years Provided: 2000 to 2022. British Columbia Ministry of Health [publisher]. Data Extract. MOH (2024). Available: http:\/\/www.health.gov.bc.ca\/data\/."},{"key":"2026072905050795000_2026.07.23.26358700v1.68","unstructured":"Canadian Institute for Health Information. National Ambulatory Care Reporting System (NACRS), 2024. Available: http:\/\/www.health.gov.bc.ca\/data\/."},{"key":"2026072905050795000_2026.07.23.26358700v1.69","unstructured":"British Columbia Ministry of Health [creator] (2024). Client Roster. British Columbia Ministry of Health [publisher]. Data Extract. MOH (2024). Available: http:\/\/www.health.gov.bc.ca\/data\/."},{"key":"2026072905050795000_2026.07.23.26358700v1.70","unstructured":"British Columbia Ministry of Health [Publisher] Data Extract MOH. British Columbia Ministry of Social Development and Poverty Reduction, 2024. Available: http:\/\/www.health.gov.bc.ca\/data\/."},{"key":"2026072905050795000_2026.07.23.26358700v1.71","unstructured":"Government of British Columbia. Personal Health Identification [Available from: https:\/\/www2.gov.bc.ca\/gov\/content\/health\/health-drug-coverage\/msp\/bc-residents\/personal-health-identification."},{"key":"2026072905050795000_2026.07.23.26358700v1.72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2016.10.003"},{"key":"2026072905050795000_2026.07.23.26358700v1.73","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-012-2833-7"},{"key":"2026072905050795000_2026.07.23.26358700v1.74","doi-asserted-by":"publisher","DOI":"10.1111\/add.15737"},{"key":"2026072905050795000_2026.07.23.26358700v1.75","doi-asserted-by":"publisher","DOI":"10.64898\/2025.11.30.25341316"},{"key":"2026072905050795000_2026.07.23.26358700v1.76","unstructured":"Mondol MH , Min J , Kurz M , Zanette M , Hossain MdB , Bach P , et al. Comparative effectiveness of missed dose protocols of opioid agonist treatment in British Columbia, Canada: A population-based observational study protocol. BMJ Open. (Under review)."},{"key":"2026072905050795000_2026.07.23.26358700v1.77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108647"},{"key":"2026072905050795000_2026.07.23.26358700v1.78","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyaa057"},{"key":"2026072905050795000_2026.07.23.26358700v1.79","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyaa223"},{"key":"2026072905050795000_2026.07.23.26358700v1.80","first-page":"e068729","article-title":"Comparative effectiveness of urine drug screening strategies alongside opioid agonist treatment in British Columbia, Canada: a population-based observational study protocol. BMJ Open","volume":"13","year":"2023","journal-title":"British Medical Journal Publishing Group"},{"key":"2026072905050795000_2026.07.23.26358700v1.81","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-036102"},{"key":"2026072905050795000_2026.07.23.26358700v1.82","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-019-00494-6"},{"key":"2026072905050795000_2026.07.23.26358700v1.83","unstructured":"BC Ministry of Health. B.C. Health System Strategy: Geographic Service Areas. 2016."},{"key":"2026072905050795000_2026.07.23.26358700v1.84","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"2026072905050795000_2026.07.23.26358700v1.85","unstructured":"College of Pharmacists of British Columbia. Changes to the Delivery Requirements for OAT Now In Effect 2020 [Available from: https:\/\/www.bcpharmacists.org\/news\/changes-delivery-requirements-oat-now-effect accessed Sep. 17 2024."},{"key":"2026072905050795000_2026.07.23.26358700v1.86","doi-asserted-by":"publisher","DOI":"10.1111\/add.15515"},{"key":"2026072905050795000_2026.07.23.26358700v1.87","unstructured":"British Columbia Centre on Substance Use. COVID-19: Information for Opioid Agonist Treatment Prescribers and Pharmacists 2020 [Available from: https:\/\/www.bccsu.ca\/wp-content\/uploads\/2020\/05\/COVID-19-Bulletin-May-20-2020.pdf accessed Sep. 17 2024."},{"key":"2026072905050795000_2026.07.23.26358700v1.88","unstructured":"Oetter HM. COVID-19: Important update from the registrar: College of Physicians and Surgeons of British Columbia; 2020 [Available from: https:\/\/www.cpsbc.ca\/files\/pdf\/2020-03-24-COVID-19-Update-from-the-Registrar.pdf accessed Sep. 17 2024."},{"key":"2026072905050795000_2026.07.23.26358700v1.89","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780091214"},{"key":"2026072905050795000_2026.07.23.26358700v1.90","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200009000-00011"},{"key":"2026072905050795000_2026.07.23.26358700v1.91","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00671.x"},{"key":"2026072905050795000_2026.07.23.26358700v1.92","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn164"},{"key":"2026072905050795000_2026.07.23.26358700v1.93","doi-asserted-by":"publisher","DOI":"10.1136\/jech.2004.029496"},{"key":"2026072905050795000_2026.07.23.26358700v1.94","doi-asserted-by":"publisher","DOI":"10.1177\/0962280210386207"},{"key":"2026072905050795000_2026.07.23.26358700v1.95","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2022.107127"},{"key":"2026072905050795000_2026.07.23.26358700v1.96","doi-asserted-by":"publisher","DOI":"10.1080\/00031305.2013.783880"},{"key":"2026072905050795000_2026.07.23.26358700v1.97","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2025-098990"},{"key":"2026072905050795000_2026.07.23.26358700v1.98","unstructured":"Bromley L KMRLSAWJ . Methadone treatment for people who use fentanyl: Recommendations. Toronto, ON: META:PHI [Internet]. 2021 [cited 2024 Mar 22]. https:\/\/www.metaphi.ca\/. Accessed 22 Mar 2024"},{"key":"2026072905050795000_2026.07.23.26358700v1.99","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000166"},{"key":"2026072905050795000_2026.07.23.26358700v1.100","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-095198"},{"key":"2026072905050795000_2026.07.23.26358700v1.101","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000156"},{"key":"2026072905050795000_2026.07.23.26358700v1.102","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2018.06.003"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.07.23.26358700","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:05:14Z","timestamp":1785326714000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2026.07.23.26358700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":102,"URL":"https:\/\/doi.org\/10.64898\/2026.07.23.26358700","relation":{},"subject":[],"published":{"date-parts":[[2026,7,27]]},"subtype":"preprint"}}